Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.
about
Different Facets of Copy Number Changes: Permanent, Transient, and AdaptiveAddressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapiesNovel CHOP activator LGH00168 induces necroptosis in A549 human lung cancer cells via ROS-mediated ER stress and NF-κB inhibitionThe efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC).A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancerAmphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathway.Enhanced Anticancer Activity of PF-04691502, a Dual PI3K/mTOR Inhibitor, in Combination With VEGF siRNA Against Non-small-cell Lung CancerEfficacy and safety of icotinib in treating non-small cell lung cancer: a systematic evaluation and meta-analysis based on 15 studies.Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies.Aesthetic Surgery in Patients with Lung Cancer: A Paradigm Shift.Morphologic and Metabolic Comparison of Treatment Responsiveness with 18Fludeoxyglucose-Positron Emission Tomography/Computed Tomography According to Lung Cancer Type.Asiatic acid inhibits lung cancer cell growth in vitro and in vivo by destroying mitochondria.Contribution of upregulated dipeptidyl peptidase 9 (DPP9) in promoting tumoregenicity, metastasis and the prediction of poor prognosis in non-small cell lung cancer (NSCLC).Cost-effectiveness analysis of the addition of bevacizumab to chemotherapy as induction and maintenance therapy for metastatic non-squamous non-small-cell lung cancer.Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma.Association of Uba6-Specific-E2 (USE1) With Lung Tumorigenesis.Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC.Response to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma with the Rare Epidermal Growth Factor Receptor Mutation S768I: a Retrospective Analysis and Literature Review.Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview.Current status of research and treatment for non-small cell lung cancer in never-smoking females.Niclosamide enhances the antitumor effects of radiation by inhibiting the hypoxia-inducible factor-1α/vascular endothelial growth factor signaling pathway in human lung cancer cells.Bone Marrow Derived Mesenchymal Stem Cells Involve in the Lymphangiogenesis of Lung Cancer and Jinfukang Inhibits the Involvement In Vivo.Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine.ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy.Hitherto unseen survival in an ALK-positive-patient with advanced stage adult ganglioneuroblastoma treated with personalized medicine.Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3.Shenfu Injection Adjunct with Platinum-Based Chemotherapy for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis and Systematic Review.Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer.CD38 knockout suppresses tumorigenesis in mice and clonogenic growth of human lung cancer cells.Value of (18)F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients.Cell death-based treatment of lung adenocarcinoma.Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA.Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer.Inverse correlation between galectin-4 and TTF-1 in lung adenocarcinoma.Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model.#2714, a novel active inhibitor with potent G2/M phase arrest and antitumor efficacy in preclinical models.Combination of long noncoding RNA MALAT1 and carcinoembryonic antigen for the diagnosis of malignant pleural effusion caused by lung cancer.Serum magnesium levels and lung cancer risk: a meta-analysis.
P2860
Q26769649-67557423-0D06-4DDD-A2BD-1703811044CAQ28074716-E3DB8ACA-284F-4D71-9280-364870AF3002Q28822272-7B8E043A-1576-4512-A54C-C2AFBE17C5F6Q33437650-A48E3CFD-A27A-49E9-8C40-47CBF5BB6EECQ33689021-249BD6AA-FADE-491A-B1AC-4B46A8C8837EQ33784481-FD4C59FE-0762-4DCA-868D-54E6CE178370Q36192506-643EF17A-D30D-4D7A-B741-0C80B6EF248BQ36205327-49EF010D-7E0D-4243-B298-2C3DC8E49D0DQ37330932-C253E506-CAAF-4BA5-8146-471515BD33FDQ37395212-2BAF4F6F-9983-459E-8CF9-AA5407363F5AQ37395352-22DBC559-65B3-4A6B-9A62-FC2BFA2E0B21Q37587297-108874D6-9DE6-43B7-BF01-8F3190DC9CD1Q37663903-85964F28-E0BE-420F-9AC9-3F3C491603B9Q38369105-BDE256C2-ABE5-4A99-91E7-DD0A1CA90BD6Q38694431-D78C4FB9-6930-4416-A0C5-5D6F3B8AC1F7Q38708954-155DF81A-24E7-4340-B33B-AFEF79133336Q38840383-C61D965A-2CFE-4F0A-9B32-2993538626A1Q38931077-ADEE8394-4A44-4F22-9F6B-416CDBC7DB73Q38989374-C3FF0B0B-BA20-4EF8-A757-A08B42EA27E7Q39298725-84BF9638-D53C-4E06-BA6E-2ACA0AD0CB29Q40104743-FB27B9B7-B9BB-42FB-A1CC-5114C6CB3246Q41396023-5C2C58D1-3567-4EAF-A9DB-6C317AB3A3B9Q43973311-1F9F839D-9AFC-4C14-90C7-92CA5EB14A6BQ46603813-60E75955-A363-4D05-B732-E990452F2550Q47124811-63E27AE0-8896-44A2-8769-C6C373B06BF9Q47146342-D1C61F84-7222-4433-9D49-15559449FDBAQ47156771-140DFAFA-3390-4B82-A2FB-A5192C341F1AQ47220604-17B8A5CB-F93F-4520-B785-4FE6C3148AC6Q47307445-1C934C98-BE33-44A6-BFA1-A25A8CB0060CQ47574237-94D17D53-2D74-44DA-9D99-E0BB223D0284Q47711273-118EB9B6-383B-4958-956A-7594F1B62AC9Q49307383-2B4C56F5-04F6-427C-A6CE-9D00E33238D2Q49417517-A767D9B7-4382-4CCE-8D00-B77C519A7798Q51823617-D0E2B03E-CD8E-40B4-A36F-B9FF12D42C53Q52633438-BC915076-8B00-4856-849C-B3D8CDF4A494Q52659225-88ADF2E3-8676-476F-8DE9-52CBEEC58FC8Q55088809-38072E26-2462-4CBA-A3EB-77D58A0FB807Q55563949-96541E19-6361-438F-BA6C-18BFB30B57AF
P2860
Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Targeted therapies for treatme ...... ances and future perspectives.
@en
type
label
Targeted therapies for treatme ...... ances and future perspectives.
@en
prefLabel
Targeted therapies for treatme ...... ances and future perspectives.
@en
P2860
P356
P1476
Targeted therapies for treatme ...... ances and future perspectives.
@en
P2093
Joan Minguet
P2860
P304
P356
10.1002/IJC.29915
P577
2015-11-04T00:00:00Z